Phase 1 Multiple Sclerosis Trial, Recruiting NCT07139743 Sponsor: Autolus Limited Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 1 Multiple Sclerosis Trial, Recruiting

NCT07139743
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form agreeing to take part in the study.
  • You are able and willing to follow the study schedule and meet all the study requirements.
  • You are between 18 and 60 years old (inclusive) at the time of signing the consent form.
  • If you are female, you are not currently pregnant or breastfeeding.
  • You have been diagnosed with PMS (Primary or Progressive Multiple Sclerosis — confirm with trial site).
  • You have previously been treated with 2 disease-modifying therapies (medicines used to alter the course of your condition).

Who may not be able to join:

  • You are currently taking certain medications that are not allowed under the study rules (confirm with trial site which medications are restricted).
  • You have a highly active form of multiple sclerosis.
  • You have been diagnosed with another autoimmune condition affecting the brain or spinal cord.
  • You currently have an active or uncontrolled fungal, bacterial, or viral infection.
  • You have a history of cancer, unless you have been free of the disease for at least 24 months.
  • You have had a transplant of the heart, lungs, kidneys, liver, or blood stem cells at any point in the past.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +44 (0)203 911 4385

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Autolus Limited
Registry
ClinicalTrials.gov
Start date
4 August 2025
Est. completion
15 August 2029

Where this trial is recruiting

🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Percentage of participants receiving obe-cel who experience dose-limiting toxicities (DLTs)); To evaluate the safety of obe-cel in participants with refractory forms of progressive multiple sclerosis (PMS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov